Document is current
Any future updates will be listed below
-
Authors
Chifotides, Helen T. http://orcid.org/0000-0001-8044-4960
Bose, Prithviraj http://orcid.org/0000-0002-4343-5712
Verstovsek, Srdan http://orcid.org/0000-0002-6912-8569
-
Funding
Funding for this research was provided by:
national cancer institute (P30 CA016672)
- License Information
-
More Information
Article History
Received: 12 July 2021
Accepted: 30 August 2021
First Online: 19 January 2022
Declarations
:
: Not applicable.
: Not applicable.
: P.B. reports honoraria from Incyte, Celgene (now BMS), CTI BioPharma, Kartos, Novartis, Sierra Oncology, and Blueprint Medicines; and research support from Incyte, Celgene (now BMS), CTI BioPharma, Kartos, Blueprint Medicines, Constellation, Astellas, Pfizer, NS Pharma, and Promedior. S.V. received research funding from Sierra Oncology, Incyte Corporation, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma Corporation, Genentech, Blueprint Medicines Corporation, Novartis, PharmaEssentia, AstraZeneca, Italfarmaco, Protagonist Therapeutics, Constellation Pharmaceuticals, Kartos Therapeutics, Prelude Therapeutics, AbbVie, Telios Pharmaceuticals, and Galecto. H.T.C. declares no conflicts of interest.
